Hypoxia-inducible factor 1-alpha (HIF-1α) is the oxygen-regulated subunit of the HIF-1 transcription factor complex. Under hypoxic conditions, HIF-1α escapes proteasomal degradation and translocates to the nucleus, where it dimerizes with constitutively expressed HIF-1β (ARNT) to activate genes involved in adaptation to low oxygen[@wang1995].
In neurodegenerative diseases, HIF-1α plays complex roles: while its activation can be neuroprotective by promoting glycolysis, angiogenesis, and erythropoiesis, chronic or dysregulated HIF-1α signaling may contribute to neuroinflammation and neuronal dysfunction[@chou2017].
¶ Structure and Domains
HIF-1α contains:
- bHLH domain (1-80): Basic helix-loop-helix DNA binding
- PAS-A domain (90-199): Dimerization with HIF-1β
- PAS-B domain (201-329): Additional dimerization interface
- ODD domain (401-603): Oxygen-dependent degradation domain
- Pro402, Pro564: Prolyl hydroxylation targets
- Asn803: Asparaginyl hydroxylation site
- TAD-N (531-575): N-terminal transactivation domain
- TAD-C (786-826): C-terminal transactivation domain
Oxygen sensing mechanism: Under normoxia, prolyl hydroxylases (PHDs) hydroxylate Pro402 and Pro564, enabling von Hippel-Lindau (pVHL) E3 ligase binding and proteasomal degradation[@jaakkola2001].
When oxygen is limited:
- PHD inactivation: Reduced prolyl hydroxylation
- HIF-1α stabilization: Half-life increases from <5 min to >60 min
- Nuclear translocation: HIF-1α enters nucleus
- Dimerization: Forms HIF-1α/HIF-1β heterodimer
- DNA binding: Binds hypoxia response elements (HREs)
- Transcription: Activates target genes
HIF-1α regulates >200 genes involved in:
| Category |
Representative Genes |
| Glycolysis |
GLUT1, HK2, LDHA, PDK1 |
| Angiogenesis |
VEGF, ANGPT2, PDGF |
| Erythropoiesis |
EPO (erythropoietin) |
| Iron metabolism |
Transferrin, TFRC, DMT1 |
| pH regulation |
CA9, CA12 (carbonic anhydrases) |
| Cell survival |
BNIP3, NIX (mitophagy) |
| Inflammation |
iNOS, COX-2 |
- Development: Embryonic survival requires HIF-1α
- Ischemia adaptation: Limits tissue damage during stroke
- Wound healing: Promotes revascularization
- Exercise: Muscle adaptation to training
HIF-1α shows complex alterations in AD[@ogunshola2009]:
- Reduced HIF-1α: Lower levels in AD hippocampus and cortex
- Impaired hypoxia response: Blunted transcriptional activation
- Aβ effects: Acute Aβ induces HIF-1α; chronic exposure suppresses it
- Tau pathology: Tau may interfere with HIF-1α nuclear translocation
- Cerebral hypoperfusion: Vascular dysfunction creates chronic low-grade hypoxia
Evidence: Reduced HIF-1α target gene expression correlates with cognitive decline in AD patients[@liu2023].
- Dopaminergic vulnerability: Substantia nigra has high oxygen demand
- HIF-1α neuroprotection: Stabilization protects dopaminergic neurons
- Iron dysregulation: Altered HIF-1α affects iron homeostasis
- DJ-1 interaction: DJ-1 (PARK7) stabilizes HIF-1α under oxidative stress
Therapeutic angle: Erythropoietin (EPO) and HIF prolyl hydroxylase inhibitors show promise in PD models[@lee2020].
¶ Stroke and Ischemia
- Acute activation: HIF-1α rapidly induced after ischemic stroke
- Dual roles: Protective (glycolysis, angiogenesis) and damaging (inflammation, BBB breakdown)
- Timing matters: Early activation protective; delayed may be harmful
- Preconditioning: Brief hypoxia activates HIF-1α and induces tolerance
- Mitochondrial dysfunction: Impaired oxidative phosphorylation
- **HIF-1α dysregulation: Reduced nuclear HIF-1α in HD models
- PDK1: HIF-1α target that inhibits pyruvate dehydrogenase
- Metabolic shift: HD neurons show impaired glycolytic adaptation
- Motor neuron hypoxia: High metabolic demand, vulnerable to ischemia
- HIF-1α targets: EPO, VEGF show neuroprotective effects
- TDP-43 interaction: May affect HIF-1α regulation
- SOD1: Mutant SOD1 may alter HIF-1α stability
Drugs that inhibit PHDs, stabilizing HIF-1α[@gupta2017]:
- Roxadustat (FG-4592): FDA-approved for anemia in CKD
- Daprodustat (GSK1278863): Also approved for anemia
- Vadadustat (AKB-6548): In clinical development
- Molidustat (BAY 85-3934): Approved in Japan
Neurodegeneration potential: HIF-PHIs may protect neurons by activating hypoxia adaptation pathways without actual hypoxia.
HIF-1α target with neuroprotective properties[@xiong2023]:
- Mechanisms: Anti-apoptotic, anti-inflammatory, angiogenic
- BBB penetration: Limited, but intranasal delivery possible
- Clinical trials: Mixed results in stroke; ongoing in MS
¶ DMOG and Other PHD Inhibitors
- DMOG: Research tool, stabilizes HIF-1α
- FG-4497: Neuroprotective in stroke models
- CoCl2: Classical hypoxia mimetic (toxicity limits use)
- Resveratrol: May stabilize HIF-1α
- Curcumin: Complex effects on HIF pathway
- Exercise: Physiological HIF-1α activation
| Interactor |
Relationship |
Disease Relevance |
| HIF-1β/ARNT |
Dimerization partner |
DNA binding |
| pVHL |
E3 ligase, targets for degradation |
Normoxic turnover |
| PHD1-3 |
Prolyl hydroxylases |
Oxygen sensing |
| FIH |
Asparaginyl hydroxylase |
Transactivation control |
| p300/CBP |
Coactivators |
Transcription |
| HSP90 |
Chaperone, stabilizes HIF-1α |
Protein stability |
| mTOR |
Activates HIF-1α translation |
Metabolic integration |
- Wang GL et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer. Proc Natl Acad Sci USA. 1995;92(12):5510-5514, https://doi.org/10.1073/pnas.92.12.5510 (1995))
- Chou A et al. The hypoxia-inducible factor-1 in neurodegeneration. Neuroscientist. 2017;23(4):408-419, https://doi.org/10.1177/1073858416669088 (2017))
- Jaakkola P et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468-472, https://doi.org/10.1126/science.1059796 (2001))
- Ogunshola OO, Antoniou X. Contribution of hypoxia to Alzheimer's disease: Is HIF-1α a mediator of neurodegeneration? Cell Mol Life Sci. 2009;66(22):3555-3563, https://doi.org/10.1007/s00018-009-0108-1 (2009))
- Liu J et al. HIF-1α signaling in Alzheimer's disease: New insights and therapeutic implications. Ageing Res Rev. 2023;90:102010, https://doi.org/10.1016/j.arr.2023.102010 (2023))
- Lee J et al. HIF prolyl hydroxylase inhibition protects dopaminergic neurons in models of Parkinson's disease. Exp Neurol. 2020;329:113274, https://doi.org/10.1016/j.expneurol.2020.113274 (2020))
- Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors. Kidney Int. 2017;92(4):788-801, https://doi.org/10.1016/j.kint.2017.06.014 (2017))
- Xiong T et al. Erythropoietin for neonatal brain injury. Cochrane Database Syst Rev. 2023;4:CD004753, https://doi.org/10.1002/14651858.CD004753.pub6 (2023))